Tolterodine: Experience-sharing interview with Dr Colin Teo
Elderly patients on androgen deprivation therapy (ADT) as part of prostate cancer treatment may be at an increased risk of depression, a recent study states.
Research on the role of circulating tumour DNA (ctDNA) in metastatic castration-resistant prostate cancer (mCRPC) gains momentum, as a new study finds ctDNA assessment promising in the monitoring and prognosis of mCRPC and in identifying new therapeutic targets for the disease.
A recent study presented at the ASCO Genitourinary Cancers Symposium 2017 held in Orlando, Florida, US showed that antibiotic use in patients with metastatic renal cell carcinoma (mRCC) may dampen the efficacy of PD-1/PD-L1 inhibitors.
Patients with castration-resistant prostate cancer (CRPC) may be able to reduce treatment cost by taking low-dose abiraterone acetate with a low-fat breakfast as a study shows noninferiority of the regimen compared with standard dosing on an empty stomach.
A combination of chemotherapy and androgen deprivation therapy (ADT) is recommended for men with extensive hormone-sensitive prostate cancer, according to a presentation at the 14th Urological Association of Asia (UAA) Congress 2016 held in Singapore.